title: Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.
abstract: In the present study, we sought to define the importance of serum IgA (sIgA)-mediated immunity in HIV-2 infection. Serum samples from a total of 29 HIV-2-infected patients from Guinea-Bissau (n = 20) and Portugal (n = 9) were studied. Samples from seronegative individuals were used as controls. Antibody reactivity to native and recombinant envelope glycoproteins as well as peptides representing various regions of the envelope glycoproteins was investigated. Furthermore, the capacity of purified IgA to neutralize the HIV-2(SBL6669) strain was tested. All serum samples showed IgA reactivity against whole HIV-2 antigen. Twenty-eight out of 29 IgA samples (96%) reacted with native HIV-2 gp125, 26/29 (90%) with recombinant gp105, and 29/29 (100%) with recombinant gp36. When using peptides, the most prominent IgA reactivity was seen against the peptide representing aa 644-658 of the transmembranous protein gp36, to which 72% of the sera reacted. Purified sIgA antibodies showed neutralizing effects against HIV-2(SBL6669) in 17/29 cases (59%). This work describes the HIV-2-specific sIgA antigenic response. Moreover, our findings show, for the first time, that sIgA may play a role in the in vitro neutralization of HIV-2.
authors.affiliation: Microbiology and Tumorbiology Center, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Qin
authors.initials: Q
authors.lastname: Lizeng
authors.forename: Pia
authors.initials: P
authors.lastname: Skott
authors.forename: Samer
authors.initials: S
authors.lastname: Sourial
authors.forename: Charlotta
authors.initials: C
authors.lastname: Nilsson
authors.forename: Sören
authors.initials: S
authors.lastname: Andersson S
authors.forename: Mariethe
authors.initials: M
authors.lastname: Ehnlund
authors.forename: Nuno
authors.initials: N
authors.lastname: Taveira
authors.forename: Ewa
authors.initials: E
authors.lastname: Björling
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000595:Amino Acid Sequence; D004797:Enzyme-Linked Immunosorbent Assay; D015686:Gene Products, env / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology* / Q000302:isolation & purification; D007074:Immunoglobulin G / Q000097:blood; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D011498:Protein Precursors / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus
chemical_list: D015686:Gene Products, env; D015483:HIV Antibodies; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D010446:Peptide Fragments; D011498:Protein Precursors; D054299:env Gene Products, Human Immunodeficiency Virus; C066316:gp125 envelope protein, Human immunodeficiency virus 2